Ranka VK - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.

Kondo S, Tajimi M, Funai T, Inoue K, Asou H, Ranka VK, Wacheck V, Doi T. Kondo S, et al. Among authors: ranka vk. Invest New Drugs. 2020 Dec;38(6):1836-1845. doi: 10.1007/s10637-020-00968-5. Epub 2020 Jun 23. Invest New Drugs. 2020. PMID: 32578154 Free PMC article. Clinical Trial.

Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.

Kondo S, Tajimi M, Funai T, Inoue K, Asou H, Ranka VK, Wacheck V, Doi T. Kondo S, et al. Among authors: ranka vk. Invest New Drugs. 2020 Dec;38(6):1846. doi: 10.1007/s10637-020-00981-8. Invest New Drugs. 2020. PMID: 32894386 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2 results

Search Page

Filters